Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery
In Vivo · 2026-07 · 40 (4) · 2280-2288
DOI: 10.21873/invivo.14380 ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vivo, online erschienen am 30.06.2026. Verfasst von Nobuki Furubayashi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan furubayashi.nobuki.yc@mail.hosp.go.jp. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents, Immunological. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan furubayashi.nobuki.yc@mail.hosp.go.jp.
- Department of Urology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Zitieren
APA
Furubayashi, N., Kojima, T., Nakano, Y., Kataoka, A., Nakamura, M., & Negishi, T. (2026). Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery. In Vivo, 40(4), 2280-2288. https://doi.org/10.21873/invivo.14380
Vancouver
Furubayashi N, Kojima T, Nakano Y, Kataoka A, Nakamura M, Negishi T. Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery. In Vivo. 2026;40(4):2280-2288. doi:10.21873/invivo.14380
BibTeX
@article{Furubayashi2026,
author = {Furubayashi, Nobuki and Kojima, Takehito and Nakano, Yasuhiro and Kataoka, Akari and Nakamura, Motonobu and Negishi, Takahito},
title = {Real-world Implementation of Adjuvant Pembrolizumab for High-risk Clear-cell Renal Cell Carcinoma After Surgery},
journal = {In Vivo},
year = {2026},
volume = {40},
number = {4},
pages = {2280--2288},
doi = {10.21873/invivo.14380}
}
EUVIMED